LOS ANGELES, June 19, 2018 /PRNewswire-PRWeb/ -- Bioanomaly, Inc., d/b/a Quanta ("Quanta") today announced that it has
Quanta's proprietary technology increases bio-energy within cannabinoids and other naturally occurring elements, at the sub atomic level which increases performance and reduces side effects. Currently, the company is expanding rapidly in multiple sectors including the legal cannabis market. Cheryl Shuman, world renowned cannabis expert and founder of the Beverly Hills Cannabis Club, calls Quanta, "the Intel Inside of Cannabis" and a "game changer" for the high-end consumer. The company drives revenue by applying its technology to existing product lines via licensing/co-branding partnerships with large brands and through direct sales of non-cannabis products in stores and online.
Quanta is headquartered in Los Angeles, CA and will continue its business as a wholly-owned subsidiary of the Company. The Company's management consists of Quanta's management team and includes Chairman and Chief Executive Officer Eric Rice, President Jeff Doiron and Executive Vice President Blake Gillette.
"We are extremely excited for the future at Quanta. As a public company we will have the unique ability to tell our story and access capital in a much more efficient manner. It is an exciting time in cannabis, science and the markets as a whole, we hope to lead the way in creating new standards of quality," said Eric Rice, CEO of Quanta.
The Company completed the reverse merger in exchange for 25,900,000 shares of the Company's common stock with Quanta becoming a wholly-owned subsidiary of the Company. In addition, the Company consummated an offering of 6,500,000 shares of its common stock for proceeds of $1,300,000. Following the reverse merger and the offering, the Company had approximately 40,900,000 shares of stock outstanding. In connection with the merger, the Company approved a change of its name to Quanta, Inc.
Quanta is an applied science company focused on increasing energy levels in plant matter (including cannabis) to increase performance within the human body. Our proprietary technology uses quantum mechanics to increases bio-activity of targeted molecules to enhance the desired effects. We specialize in potentiating naturally occurring elements to create impactful and sustainable healing solutions that are as powerful and predictable as pharmaceutical drugs.
We offer our technology as a platform, making it accessible to existing high-quality product makers with existing distribution channels. Quanta works alongside high-quality cannabis, nutraceutical, phytoceutical and wellness brands to increase performance of product lines. Our mission is to power as many impactful, high-performing wholly organic products as possible through a series of licensing and distribution partnerships.
Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Follow Quanta: Facebook: https://www.facebook.com/quantatechnology/ Twitter: https://twitter.com/Quanta_tech Instagram: https://www.instagram.com/quanta_technology/ Pinterest: https://www.pinterest.com/quantatechnology/pins/ Vimeo Video: https://vimeo.com/254024002
Subscribe to our Free Newsletters!
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...
Complex regional pain syndrome (CRPS) is rare chronic pain disorder usually involving an arm or ...View All